What are GLP-1 agonists?

Wegovy (semaglutide), Ozempic (semaglutide for diabetes), and Mounjaro (tirzepatide) are GLP-1 (glucagon-like peptide-1) receptor agonists. They strongly suppress appetite and slow gastric emptying, producing weight loss. Average 15-20% body weight reduction is reported with one year of use.

What is Ozempic face?

An informal term for facial changes seen in users who have undergone rapid weight loss with GLP-1 agonists. Not a medical term, but consistently observed clinically. Facial fat compartments (notably infraorbital, temporal, and zygomatic) deplete rapidly, producing hollowing and laxity that resemble accelerated aging.

Are there ways to mitigate facial aging while using GLP-1 drugs?

No silver bullet, but options include: maintaining protein intake (1.2-1.6g per kg body weight daily), strength training, collagen/peptide supplementation, topical anti-aging (retinol, peptides, vitamin C), and aesthetic adjuncts (filler, biostimulators). Most important is pacing the weight loss; gradual reduction over 6-12 months produces gentler facial changes than rapid loss.

Ozempic Face: 63% of U.S. Med Spa Patients Added Aesthetic Procedures After GLP-1

The explosive growth of the GLP-1 drug market is generating a new category in aesthetic medicine. Wegovy, Ozempic, and Mounjaro users undergoing rapid weight loss are seeing consistent facial fat compartment loss in clinical settings, and a survey of 174 U.S. medical spas found that 63% of patients did not seek aesthetic procedures before weight loss but added new procedures afterward.

What changes occur

Rapid weight loss via GLP-1 agonists depletes facial fat compartments differentially. The largest losses reported clinically:

Medial cheek fat pad: volume below the cheekbone, leading to depression
Sub-orbicularis oculi fat: under the eye, producing infraorbital hollowing
Temporal fat pad: temple area, generating temporal concavity
Submental fat: jawline blurring and laxity

The composite impression is “facial aging accelerated by 5-10 years.” Medically this is fat redistribution, not aging, but visually the two are difficult to distinguish.

Med spa market shifts

The U.S. survey of 174 medical spas quantified the change.

63% of patients: did not seek aesthetic procedures before weight loss, added them after
U.S. aesthetic patients spending $160 million per month on weight-loss-related treatments
Most-added procedures: filler (especially infraorbital and temporal), thread lifts, collagen biostimulators (Sculptra), polynucleotides

This is not simply because GLP-1 use rose; the side effects of GLP-1 generated entirely new aesthetic demand. A “weight loss → new aesthetic problem → new procedure revenue” cycle has formed.

”Reconstructive skincare” as a new label

Aesthetic clinicians have begun grouping the trend under “reconstructive skincare.” Where “maintenance skincare” focused on slowing the rate of aging, reconstructive skincare emphasizes reversing rapid changes.

A recent example is a serum formulation marketed for GLP-1 users: water base, 20 peptides, sodium hyaluronate, plant antioxidants, and a bioavailable retinoic acid derivative formulated to penetrate the dermal layer and synergistically stimulate collagen and elastin synthesis. A “GLP-1 companion topical” category has effectively emerged.

Beyond the face

Two reasons this trend transcends a simple aesthetic story.

First, concurrent muscle mass loss. About 25-40% of weight loss with GLP-1 agonists is reported as muscle loss. The facial fat compartment loss is the visible expression of co-occurring muscle and fat loss; the same mechanism plays out in limb musculature. Limb muscle loss can become the entry point for sarcopenia in later life, which is why protein intake and strength training have moved to the front of post-GLP-1 guidance.

Second, skin laxity and collagen loss together. Rapid weight loss doesn’t give the dermal collagen and elastin time to remodel. Two patients losing the same total weight may show very different skin laxity depending on pace. A year-long gradual reduction allows collagen-elastin adaptation; rapid 6-month loss produces marked skin laxity.

Prescribing guidance shifts

Some U.S. clinics have already adopted these as standard protocol when prescribing GLP-1 agonists.

Protein intake: 1.2-1.6g per kg body weight daily (72-96g/day for 60kg body)
Strength training: 2-3 resistance sessions per week
Nutritional support: protein supplements, collagen peptides, vitamin D, vitamin K2, magnesium
Pace the loss: 15-20% over a year (1-1.5% per month)
Topical anti-aging: retinol, peptides, vitamin C, hyaluronic acid
Aesthetic adjuncts (when indicated): filler, biostimulators, thread lifts

Korean clinics rolling out Wegovy prescriptions are settling on similar guidance.

What to verify

GLP-1 agonists are an effective option for obesity, but the following considerations apply.

Align with prescriber on weight loss target and pace
Periodic bone density and muscle mass monitoring (DXA)
Protein + strength training during use
Awareness of weight regain post-discontinuation (potential lifelong medication)
Aesthetic procedures can be performed during use, not only after

What’s next

The GLP-1-era aesthetic market is hardening around the chain of “weight loss → aesthetic side effect → adjacent market.” Topical anti-aging, aesthetic medicine, nutritional supplements, and exercise coaching are bundling into a GLP-1 companion category, and the trend will likely intensify in 2026-2027. The market is being restructured from “drug prescription” to “prescription + companion care package.”

Source: Dermatology Times / Aesthetic Survey 2025